Rapidly Establishing an Ultra-Cold Supply Chain of Vaccines in Israel: Evidence for the Efficacy of Inoculation to Mitigate the COVID-19 Pandemic

Author:

Naor Michael1ORCID,Pinto Gavriel David2,Davidov Pini23ORCID,Abdrbo Lina2

Affiliation:

1. School of Business Administration, Hebrew University, Jerusalem 9190501, Israel

2. Industrial Engineering and Management, Azrieli College of Engineering, Jerusalem 9103501, Israel

3. UNEC Cognitive Economics Center, Azerbaijan State University of Economics, Baku AZ1001, Azerbaijan

Abstract

The agenda of this research was to investigate how to mitigate the spread of coronaviruses by rapidly establishing an ultra-cold supply chain of vaccines. Data analysis was conducted by linear regression utilizing a dataset publicly available from the Israel Ministry of Health regarding the daily rates of people vaccinated, tested, hospitalized, etc., since the start of the pandemic. The data provide statistical evidence for the efficacy of the Pfizer vaccines in diminishing a wide variety of disease factors, such as the number of patients who were lightly, moderately, or severely sick, and daily deaths, as well as the rate of spread (R-ratio) and number/percentage of people infected. Insightfully, the data corroborate how the first and second doses of the vaccines were able to decrease the wave of COVID-19, which hit Israel in January 2021, while the booster third dose was able to diminish a subsequent COVID-19 wave occurring in Israel in July 2021.

Funder

Azrieli College of Engineering–Jerusalem Research Fund

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference35 articles.

1. Sinha, A., Bernardes, E., Calderon, R., and Wuest, T. (2021). Digital Supply Networks, McGraw Hill-Ascent Audio.

2. World Health Organization (2022). Operational Guidance on Establishing an Ultra-Cold Chain System in Support of the Pfizer-BioNTech COVID-19 Vaccine Rollout, 1 February 2022 (No. WHO/2019-nCoV/UCC_systems/Pfizer-BioNTech_vaccine/2022.1), World Health Organization.

3. A single dose of recombinant VSV-∆ G-spike vaccine provides protection against SARS-CoV-2 challenge;Tamir;Nat. Commun.,2020

4. Yahalom-Ronen, Y., Erez, N., Fisher, M., Tamir, H., Politi, B., Achdout, H., Melamed, S., Glinert, I., Weiss, S., and Cohen-Gihon, I. (2022). Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera. Vaccines, 10.

5. Digital health nation: Israel’s global big data innovation hub;Balicer;Lancet,2017

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3